Malignant neoplasm of placenta
In Malignant neoplasms of female genital organs (C51-C58), chapter 2: Neoplasms
- C58 is billable and valid on claims for FY 2027. If the record has more detail, check the other codes under C51-C58 below.
- As a secondary diagnosis it is not a CC or MCC, so it doesn't raise the MS-DRG payment.
- Counts toward HCC 22 (Bladder, Colorectal, and Other Cancers) in the Medicare Advantage risk model (CMS-HCC V28).
- AHRQ's Chronic Condition Indicator classes it as chronic: expected to last 12 months or longer and to limit daily life or need ongoing care.
- 11 US deaths in 2024 had an underlying cause in category C58, per the National Vital Statistics System on CDC WONDER. Death records use WHO ICD-10, so the count is for the whole category.
- Expected only on maternity records. (Maternity list)
Also indexed as: Carcinoma, chorionic, unspecified site, female; Choriocarcinoma, unspecified site, female
Advertisements
Instructional notes
Also applies, from Malignant neoplasms of female genital organs (C51-C58)
These notes sit on C51-C58 and apply to every code under it, including C58.
Includes: conditions that are coded here
- malignant neoplasm of skin of female genital organs
Official coding guidelines
From the ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027 (CMS and NCHS). Links open the PDF at the right page.
Rules for coding benign and malignant neoplasms: using the Neoplasm Table, sequencing primary and secondary sites, treatment encounters, complications, and current cancer versus personal history.
- Admission/Encounter for treatment of primary site (page 33)
- Admission/Encounter for treatment of secondary site (page 33)
- Coding and sequencing of complications (page 34)
- Primary malignancy previously excised (page 34)
- Admissions/Encounters involving antineoplastic chemotherapy, immunotherapy and radiation therapy (page 35)
- Admission/encounter to determine extent of malignancy (page 36)
- Symptoms, signs, and abnormal findings listed in Chapter 18 associated with neoplasms (page 36)
- Admission/encounter for pain control/management (page 36)
Other codes under C51-C58
Malignant neoplasms of female genital organs (C51-C58)
- C51Malignant neoplasm of vulva
- C52Malignant neoplasm of vagina
- C53Malignant neoplasm of cervix uteri
- C54Malignant neoplasm of corpus uteri
- C55Malignant neoplasm of uterus, part unspecified
- C56Malignant neoplasm of ovary
- C57Malignant neoplasm of other and unspecified female genital organs
- C58Malignant neoplasm of placenta(this code)
C58 MS-DRGs
As the principal diagnosis, C58 groups to MS-DRG 731, 732, 733, 754, 755, or 756 (v44.0). Which one applies depends on procedures performed, secondary diagnoses (CC/MCC), and the patient's age and discharge status.
- DRG 731 Uterine and Adnexa Procedures for Malignancy with MCC
- DRG 732 Uterine and Adnexa Procedures for Malignancy with CC
- DRG 733 Uterine and Adnexa Procedures for Malignancy without CC/MCC
- DRG 754 Malignancy, Female Reproductive System with MCC
- DRG 755 Malignancy, Female Reproductive System with CC
- DRG 756 Malignancy, Female Reproductive System without CC/MCC
Related conditions
Grouped by AHRQ's Clinical Classifications Software Refined (CCSR), which sorts every diagnosis code into clinically meaningful categories.
C58 is in Female reproductive system cancers - all other types (NEO038, its default category), with 18 codes. Others in it:
- C51.0 Malignant neoplasm of labium majus
- C51.1 Malignant neoplasm of labium minus
- C51.2 Malignant neoplasm of clitoris
- C51.8 Malignant neoplasm of overlapping sites of vulva
- C57.10 Malignant neoplasm of unspecified broad ligament
- C57.11 Malignant neoplasm of right broad ligament
- C57.12 Malignant neoplasm of left broad ligament
- C57.20 Malignant neoplasm of unspecified round ligament
Medicare coverage articles listing C58
These 25 Medicare billing and coding articles list C58 as a diagnosis that supports medical necessity for the services they cover. From the CMS Medicare Coverage Database; check your own contractor's article before billing.
- MolDX: Genetic Testing for Hereditary Thrombophilia (4 contractors)
- MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (4 contractors)
- MolDX: Next-Generation Sequencing for Solid Tumors (4 contractors)
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer (4 contractors)
- MolDX: Plasma-Based Genomic Profiling in Solid Tumors (4 contractors)
- Erythropoiesis Stimulating Agents (2 contractors)
- Lab: Flow Cytometry (2 contractors)
- Peripheral Nerve Blocks (2 contractors)
- Proton Beam Therapy
- CT of the Abdomen and Pelvis
And 15 more.
About the condition
Plain-language background from MedlinePlus (National Library of Medicine), not coding guidance.
Tumors and Pregnancy
Tumors during pregnancy are rare, but they can happen. Tumors can be either benign (not cancer) or malignant (cancer). The most common cancers in pregnancy include breast cancer, thyroid cancer, cervical cancer, lymphoma, and melanoma. Cancer itself rarely harms the fetus, and some cancer treatments are safe during pregnancy. You and your health care provider will work together to find the best treatment. Your choices will depend on how far along the pregnancy is, as well as the type, size, and stage of your cancer.
Read more about tumors and pregnancy on MedlinePlusCode history
Valid since FY2016, when ICD-10-CM took effect on October 1, 2015. No changes since.
ICD-9-CM equivalent
Legacy crosswalk from the CMS General Equivalence Mappings (last updated 2018).
- 181 Malignant neoplasm of placenta